Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Phenylketonuria
Interventions
DRUG

rAvPAL-PEG

0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day

Trial Locations (9)

12208

Albany Medical Center, Albany

15213

University of Pittsburgh Medical Center, Pittsburgh

32610

University of Florida, Gainesville

40202

Weisskopf Child Evaluation Center / University of Louisville, Louisville

43205

Nationwide Children's Hospital, Columbus

53705

University of Wisconsin-Madison, Madison

63110

Washington University Center for Applied Research Sciences, St Louis

65212

University of Missouri, Columbia

80045

The Children's Hospital, Aurora

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY